Corticosteroids, pregnancy, and HELLP syndrome: A review

Obstetrical and Gynecological Survey

Volumn 60, Issue 1, 2005, Pages 57-70

  Van Runnard Heimel, P J ^a   Franx, A ^a,b   Schobben, A F A M ^a   Huisjes, A J M ^c   Derks, J B ^a   Bruinse, H W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c GELRE HOSPITALS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BARBITURIC ACID DERIVATIVE; BETAMETHASONE; CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; HYDROCORTISONE; KETOCONAZOLE; PHENYTOIN; PREDNISOLONE; PREDNISONE; RIFAMPICIN;

AUTOIMMUNE DISEASE; BLOOD PLACENTA BARRIER; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DRUG ACTIVITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; FETUS DISEASE; GIANT CELL ARTERITIS; GLUCOSE INTOLERANCE; GROWTH RETARDATION; HELLP SYNDROME; HUMAN; INTRAUTERINE GROWTH RETARDATION; LOW BIRTH WEIGHT; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN MORTALITY; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PATHOLOGIC FRACTURE; POLYMYOSITIS; PREGNANCY; RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN ATROPHY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; FEMALE; HELLP SYNDROME; HUMANS; MATERNAL-FETAL EXCHANGE; PREGNANCY; RANDOMIZED CONTROLLED TRIALS;

EID: 11144291505     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ogx.0000150346.42901.07     Document Type: Review

References (177)

1. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999;180:499-506.
2. Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 1982;142:159-167.
3. Hench P, Kendall E. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Intern Med 1950;85:545-566.
4. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972;50:515-525.
5. Thiagarajah S, Bourgeois FJ, Harbert GM Jr, et al. Thrombocytopenia in preeclampsia: associated abnormalities and management principles. Am J Obstet Gynecol 1984;150:1-7.
6. Allford SL, Hunt BJ, Rose P, et al. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003;120:556-573.
7. George JN, Sadler JE, Lammle B. Platelets: thrombotic thrombocytopenic purpura. Hematology (Am Soc Hematol Educ Program) 2002;315-334.
8. Magann EF, Martin JN Jr. Critical care of HELLP syndrome with corticosteroids. Am J Perinatol 2000;17:417-422.
9. Osinski PA. Steroid 11beta-ol dehydrogenase in human placenta. Nature 1960;187:777.
10. Tomlinson JW, Stewart PM. Cortisol metabolism and the role of 11 beta-hydroxysteroid dehydrogenase. Best Pract Res Clin Endocrinol Metab 2001;15:61-78.
11. Edwards CR, Benediktsson R, Lindsay RS, et al. 11 beta-Hydroxysteroid dehydrogenases: key enzymes in determining tissue-specific glucocorticoid effects. Steroids 1996;61:263-269.
12. Krozowski Z, Li KX, Koyama K, et al. The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes. J Steroid Biochem Mol Biol 1999;69:391-401.
13. Burton PJ, Waddell BJ. Dual function of 11beta-hydroxysteroid dehydrogenase in placenta: modulating placental glucocorticoid passage and local steroid action. Biol Reprod 1999;60:234-240.
14. Melby JC. Drug spotlight program: systemic corticosteroid therapy: pharmacology and endocrinologic considerations. Ann Intern Med 1974;81:505-512.
15. Peets EA, Staub M, Symcnowicz S. Plasma binding of betamethasone-3H, dexamethasone-3H, and cortisol-14C-a comparative study. Biochem Pharmacol 1969;18:1655-1663.
16. Swartz SL, Dluhy RG. Corticosteroids: clinical pharmacology and therapeutic use. Drugs 1978;16:238-255.
17. Loew D, Schuster O, Graul EH. Dose-dependent pharmacokinetics of dexamethasone. Eur J Clin Pharmacol 1986;30:225-230.
18. Garg V, Jusko WJ. Bioavailability and reversible metabolism of prednisone and prednisolone in man. Biopharm Drug Dispos 1994;15:163-172.
19. Al-Habet S, Rogers HJ. Pharmacokinetics of intravenous and oral prednisolone. Br J Clin Pharmacol 1980;10:503-508.
20. Frey FJ. Kinetics and dynamics of prednisolone. Endocr Rev 1987;8:453-473.
21. Madsbad S, Bjerregaard B, Henriksen JH, et al. Impaired conversion of prednisone to prednisolone in patients with liver cirrhosis. Gut 1980;21:52-56.
22. Renner E, Horber FF, Jost G, et al. Effect of liver function on the metabolism of prednisone and prednisolone in humans. Gastroenterology 1986;90:819-828.
23. Frey BM, Frey FJ. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 1990;19:126-146.
24. Stewart PM, Murry BA, Mason JI. Human kidney 11 beta-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. J Clin Endocrinol Metab 1994;79:480-484.
25. Jubiz W, Meikle AW. Alterations of glucocorticoid actions by other drugs and disease states. Drugs 1979;18:113-121.
26. Petereit LB, Meikle AW. Effectiveness of prednisolone during phenytoin therapy. Clin Pharmacol Ther 1977;22:912-916.
27. Powell-Jackson PR, Gray BJ, Heaton RW, et al. Adverse effect of rifampicin administration on steroid-dependent asthma. Am Rev Respir Dis 1983;128:307-310.
28. Langhoff E, Madsen S, Olgaard K, et al. Clinical results and cyclosporine effect on prednisolone metabolism of cadaver kidney transplanted patients. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985;21:963-968.
29. Seidegard J, Simonsson M, Edsbacker S. Effect of an oral contraceptive on the plasma levels of budesonide and prednisolone and the influence on plasma cortisol. Clin Pharmacol Ther 2000;67:373-381.
30. Zurcher RM, Frey BM, Frey FJ. Impact of ketoconazole on the metabolism of prednisolone. Clin Pharmacol Ther 1989;45:366-372.
31. Bland R. Steroid hormone receptor expression and action in bone. Clin Sci (Lond) 2000;98:217-240.
32. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 1999;96:513-523.
33. Oikarinen A, Autio P. New aspects of the mechanism of corticosteroid-induced dermal atrophy. Clin Exp Dermatol 1991;16:416-419.
34. Klein NC, Go CH, Cunha BA. Infections associated with steroid use. Infect Dis Clin North Am 2001;15:423-432, viii.
35. Helfer EL, Rose LI. Corticosteroids and adrenal suppression. Characterising and avoiding the problem. Drugs 1989;38:838-845.
36. Jusko WJ. Pharmacokinetics and receptor-mediated pharmacodynamics of corticosteroids. Toxicology 1995;102:189-196.
37. Cato ACB, Wade E. Molecular mechanisms of anti-inflammatory action of glucocorticoids. BioEssays 1996;18:371-378.
38. Beato M, Klug J. Steroid hormone receptors: an update. Hum Reprod Update 2000;6:225-236.
39. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 1998;94:557-572.
40. Pitzalis C, Pipitone N, Perretti M. Regulation of leukocyte-endothelial interactions by glucocorticoids. Ann N Y Acad Sci 2002;966:108-118.
41. Riccardi C, Bruscoli S, Migliorati G. Molecular mechanisms of immunomodulatory activity of glucocorticoids. Pharmacol Res 2002;45:361-368.
42. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionary conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-260.
43. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 2003;24:488-522.
44. De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 2000;109:16-22.
45. Almawi WY, Melemedjian OK, Rieder MJ. An alternate mechanism of glucocorticoid anti-proliferative effect: promotion of a Th2 cytokine-secreting profile. Clin Transplant 1999;13:365-374.
46. Grosset C, Taupin JL, Lemercier C, et al. Leukaemia inhibitory factor expression is inhibited by glucocorticoids through post-transcriptional mechanisms. Cytokine 1999;11:29-36.
47. Nyhlen K, Linden M, Andersson R, et al. Corticosteroids and interferons inhibit cytokine-induced production of IL-8 by human endothelial cells. Cytokine 2000;12:355-360.
48. Schleimer RP. An overview of glucocorticoid anti-inflammatory actions. Eur J Clin Pharmacol 1993;45(suppl 1):S3-7; discussion S43-44.
49. Christ M, Wehling M. Cardiovascular steroid actions: swift swallows or sluggish snails? Cardiovasc Res 1998;40:34-44.
50. Jarvelainen H, Pelliniemi TT, Ronnemaa T. The stabilizing effect of glucocorticoids on human endothelial cells in culture. Scand J Clin Lab Invest 1985;45:223-228.
51. Kitchens CS, Pendergast JF. Human thrombocytopenia is associated with structural abnormalities of the endothelium that are ameliorated by glucocorticosteroid administration. Blood 1986;67:203-206.
52. Boumpas DT, Chrousos GP, Wilder RL, et al. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993;119:1198-1208.
53. Jorgensen KA, Stoffersen E. Hydrocortisone, platelet aggregation and platelet prostaglandin metabolism. Scand J Haematol 1980;25:445-447.
54. Glass F, Lippton H, Kadowitz PJ. Effects of methylprednisolone and hydrocortisone on aggregation of rabbit platelets induced by arachidonic acid and other aggregating substances. Thromb Haemost 1981;46:676-679.
55. Hutton RA, Mikhailidis D, Dormandy KM, et al. Platelet aggregation studies during transient hypoglycaemia: a potential method for evaluating platelet function. J Clin Pathol 1979;32:434-438.
56. Godfrey DI, Purton JF, Boyd RL, et al. Stress-free T-cell development: glucocorticoids are not obligatory. Immunol Today 2000;21:606-611.
57. Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function. Annu Rev Immunol 2000;18:309-345.
58. Yang Y, Mercep M, Ware CF, et al. Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas: inhibition of Fas ligand expression by retinoic acid and glucocorticoids. J Exp Med 1995;181:1673-1682.
59. Rook GA. Glucocorticoids and immune function. Baillieres Best Pract Res Clin Endocrinol Metab 1999;13:567-581.
60. Ramierz F, Fowell DJ, Puklavec M, et al. Glucocorticoids promote a TH2 cytokine response by CD4+ T cells in vitro. J Immunol 1996;156:2406-2412.
61. Wilckens T, De Rijk R. Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol Today 1997;18:418-424.
62. Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 1997;33:328-343.
63. Doe RP, Fernandez R, Seal US. Measurement of corticosteroid-binding globulin in man. J Clin Endocrinol Metab 1964; 24:1029-1039.
64. Reynolds F, Knott C. Pharmacokinetics in pregnancy and placental drug transfer. Oxf Rev Reprod Biol 1989;11:389-449.
65. Pacifici GM, Nottoli R. Placental transfer of drugs administered to the mother. Clin Pharmacokinet 1995;28:235-269.
66. Waddell WJ, Marlowe C. Transfer of drugs across the placenta. Pharmacol Ther 1981;14:375-390.
67. Audus KL. Controlling drug delivery across the placenta. Eur J Pharmacol Sci 1999;8:161-165.
68. Garland M. Pharmacology of drug transfer across the placenta. Obstet Gynecol Clin North Am 1998;25:21-42.
69. Ganapathy V, Prasad PD, Ganapathy ME, et al. Placental transporters relevant to drug distribution across the maternal-fetal interface. J Pharmacol Exp Ther 2000;294:413-420.
70. Young AM, Allen CE, Audus KL. Efflux transporters of the human placenta. Adv Drug Deliv Rev 2003;55:125-132.
71. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 2004;43:487-514.
72. Juchau MR, Chao ST, Omiecinski CJ. Drug metabolism by the human fetus. Clin Pharmacokinet 1980;5:320-339.
73. Krozowski Z, MaGuire JA, Stein-Oakley AN, et al. Immunohistochemical localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta. J Clin Endocrinol Metab 1995;80:2203-2209.
74. Levitz M, Jansen V, Dancis J. The transfer and metabolism of corticosteroids in the perfused human placenta. Am J Obstet Gynecol 1978;132:363-366.
75. Siebe H, Baude G, Lichtenstein I, et al. Metabolism of dexamethasone: sites and activity in mammalian tissues. Ren Physiol Biochem 1993;16:79-88.
76. Diederich S, Eigendorff E, Burkhardt P, et al. 11beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J Clin Endocrinol Metab 2002;87:5695-5701.
77. Benediktsson R, Calder AA, Edwards CR, et al. Placental 11 beta-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin Endocrinol (Oxf) 1997;46:161-166.
78. Murphy VE, Clifton VL. Alterations in human placental 11beta-hydroxysteroid dehydrogenase type 1 and 2 with gestational age and labour. Placenta 2003;24:739-744.
79. Shams M, Kilby MD, Somerset DA, et al. 11 Beta-hydroxysteroid dehydrogenase type 2 in human pregnancy and reduced expression in intrauterine growth restriction. Hum Reprod 1998;13:799-804.
80. McTernan CL, Draper N, Nicholson H, et al. Reduced placental 11beta-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible mechanisms. J Clin Endocrinol Metab 2001;86:4979-4983.
81. McCalla CO, Nacharaju VL, Muneyylrci-Delale O, et al. Placental 11 beta-hydroxysteroid dehydrogenase activity in normotensive and pre-eclamptic pregnancies. Steroids 1998;63:511-515.
82. Schoof E, Girstl M, Frobenius W, et al. Decreased gene expression of 11beta-hydroxysteroid dehydrogenase type 2 and 15-hydroxyprostaglandin dehydrogenase in human placenta of patients with preeclampsia. J Clin Endocrinol Metab 2001;86:1313-1317.
83. Blanford AT, Murphy BE. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol 1977;127:264-267.
84. Addison RS, Maguire DJ, Mortimer RH, et al. Pathway and kinetics of prednisolone metabolism in the human placenta. J Steroid Biochem Mol Biol 1993;44:315-320.
85. Beitins IZ, Bayard F, Ances IG, et al. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr 1972;81:936-945.
86. Ballard PL, Granberg P, Ballard RA. Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome. J Clin Invest 1975;56:1548-1554.
87. Anderson AB, Gennser G, Jeremy JY, et al. Placental transfer and metabolism of betamethasone in human pregnancy. Obstet Gynecol 1977;49:471-474.
88. Petersen MC, Nation RL, Ashley JJ, et al. The placental transfer of betamethasone. Eur J Clin Pharmacol 1980;18:245-247.
89. Smith MA, Thomford PJ, Mattison DR, et al. Transport and metabolism of dexamethasone in the dually perfused human placenta. Reprod Toxicol 1988;2:37-43.
90. Benassayag C, Souski I, Mignot TM, et al. Corticosteroid-binding globulin status at the fetomaternal interface during human term pregnancy. Biol Reprod 2001;64:812-821.
91. Ballard PL, Ballard RA. Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. Am J Obstet Gynecol 1995;173:254-262.
92. Derks JB, Mulder EJ, Visser GH. The effects of maternal betamethasone administration on the fetus. Br J Obstet Gynaecol 1995;102:40-46.
93. Mulder EJ, Koenen SV, Blom I, et al. The effects of antenatal betamethasone administration on fetal heart rate and behaviour depend on gestational age. Early Hum Dev 2004;76:65-77.
94. Wallace EM, Baker LS. Effect of antenatal betamethasone administration on placental vascular resistance. Lancet 1999;353:1404-1407.
95. Piazze JJ, Anceschi MM, La Torre R, et al. Effect of antenatal betamethasone therapy on maternal-fetal Doppler velocimetry. Early Hum Dev 2001;60:225-232.
96. Potter SM, Dennedy MC, Morrison JJ. Corticosteroids and fetal vasculature: effects of hydrocortisone, dexamethasone and betamethasone on human umbilical artery. BJOG 2002;109:1126-1131.
97. Simchen MJ, Alkazaleh F, Adamson SL, et al. The fetal cardiovascular response to antenatal steroids in severe early-onset intrauterine growth restriction. Am J Obstet Gynecol 2004;190:296-304.
98. Reinisch JM, Simon NG, Karow WG, et al. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science 1978;202:436-438.
99. Thorp JA, Jones PG, Knox E, et al. Does antenatal corticosteroid therapy affect birth weight and head circumference? Obstet Gynecol 2002;99:101-108.
100. Murphy VE, Zakar T, Smith R, et al. Reduced 11beta-hydroxysteroid dehydrogenase type 2 activity is associated with decreased birth weight centile in pregnancies complicated by asthma. J Clin Endocrinol Metab 2002;87:1660-1668.
101. Kajantie E, Dunkel L, Turpeinen U, et al. Placental 11 beta-hydroxysteroid dehydrogenase-2 and fetal cortisol/cortisone shuttle in small preterm infants. J Clin Endocrinol Metab 2003;88:493-500.
102. van Uum SH, Hermus AR, Smits P, et al. The role of 11 beta-hydroxysteroid dehydrogenase in the pathogenesis of hypertension. Cardiovasc Res 1998;38:16-24.
103. Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev 2000:CD000065.
104. Jobe AH, Soil RF. Choice and dose of corticosteroid for antenatal treatments. Am J Obstet Gynecol 2004;190:878-881.
105. Guinn DA. Repeat courses of antenatal corticosteroids: the controversy continues. Am J Obstet Gynecol 2004;190:585-587.
106. French NP, Hagan R, Evans SF, et al. Repeated antenatal corticosteroids: effects on cerebral palsy and childhood behavior. Am J Obstet Gynecol 2004;190:588-595.
107. Benediktsson R, Lindsay RS, Noble J, et al. Glucocorticoid exposure in utero: new model for adult hypertension. Lancet 1993;341:339-341.
108. Seckl JR. Glucocorticoid programming of the fetus; adult phenotypes and molecular mechanisms. Mol Cell Endocrinol 2001;185:61-71.
109. Smolders-de Haas H, Neuvel J, Schmand B, et al. Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12-year follow-up. Pediatrics 1990;86:65-70.
110. Dessens AB, Haas HS, Koppe JG. Twenty-year follow-up of antenatal corticosteroid treatment. Pediatrics 2000;105:E77.
111. Ostensen M. Optimisation of antirheumatic drug treatment in pregnancy. Clin Pharmacokinet 1994;27:486-503.
112. Bermas BL, Hill JA. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum 1995;38:1722-1732.
113. Lockshin MD, Sammaritano LR. Corticosteroids during pregnancy. Scand J Rheumatol Suppl 1998;107:136-138.
114. Namazy J, Schatz M, Long L, et al. Use of inhaled steroids by pregnant asthmatic women does not reduce intrauterine growth. J Allergy Clin Immunol 2004;113:427-432.
115. Tauscher AE, Fleischer AB Jr, Phelps KC, et al. Psoriasis and pregnancy. J Cutan Med Surg 2002;6:561-570.
116. Ferrero S, Pretta S, Ragni N. Multiple sclerosis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol 2004;115:3-9.
117. Koren G, Klinger G, Ohlsson A. Fetal pharmacotherapy. Drugs 2002;62:757-773.
118. Breur JM, Visser GH, Kruize AA, et al. Treatment of fetal heart block with maternal steroid therapy: case report and review of the literature. Ultrasound Obstet Gynecol 2004;24:467-472.
119. Roberts JM, Taylor RN, Musci TJ, et al. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989;161:1200-1204.
120. Brown MA, Lindheimer MD, de Swiet M, et al. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IX-XIV.
121. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy 2003;22:143-148.
122. Redman CW, Sargent IL. Placental debris, oxidative stress and pre-eclampsia. Placenta 2000;21:597-602.
123. Pridjian G, Puschett JB. Preeclampsia. Part 1: clinical and pathophysiologic considerations. Obstet Gynecol Surv 2002;57:598-618.
124. Vince GS, Starkey PM, Austgulen R, et al. Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol 1995;102:20-25.
125. Madazli R, Aydin S, Uludag S, et al. Maternal plasma levels of cytokines in normal and preeclamptic pregnancies and their relationship with diastolic blood pressure and fibronectin levels. Acta Obstet Gynecol Scand 2003;82:797-802.
126. Haeger M, Unander M, Norder-Hansson B, et al. Complement, neutrophil, and macrophage activation in women with severe preeclampsia and the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 1992;79:19-26.
127. Visser W, Beckmann I, Bremer HA, et al. Bioactive tumour necrosis factor alpha in pre-eclamptic patients with and without the HELLP syndrome. Br J Obstet Gynaecol 1994;101:1081-1082.
128. Haeger M, Unander M, Andersson B, et al. Increased release of tumor necrosis factor-alpha and interleukin-6 in women with the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Acta Obstet Gynecol Scand 1996;75:695-701.
129. Darmochwal-Kolarz D, Leszczynska-Gorzelak B, Rolinski J, et al. T helper 1- and T helper 2-type cytokine imbalance in pregnant women with pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 1999;86:165-170.
130. Saito S, Sakai M. Th1/Th2 balance in preeclampsia. J Reprod Immunol 2003;59:161-173.
131. Sacks G, Sargent I, Redman C. An innate view of human pregnancy. Immunol Today 1999;20:114-118.
132. Sacks GP, Redman CW, Sargent IL. Monocytes are primed to produce the Th1 type cytokine IL-12 in normal human pregnancy: an intracellular flow cytometric analysis of peripheral blood mononuclear cells. Clin Exp Immunol 2003;131:490-497.
133. Strand S, Strand D, Seufert R, et al. Placenta-derived CD95 ligand causes liver damage in hemolysis, elevated liver enzymes, and low platelet count syndrome. Gastroenterology 2004;126:849-858.
134. Martin JN Jr, Blake PG, Perry KG Jr, et al. The natural history of HELLP syndrome: patterns of disease progression and regression. Am J Obstet Gynecol 1991;164:1500-1509; discussion 1509-1513.
135. Brewster JA, Speck EH, Lindow SW. Spontaneous resolution of HELLP syndrome in a primigravida presenting at 31 weeks' gestation. J Obstet Gynaecol 2003;23:206-207.
136. Audibert F, Friedman SA, Frangieh AY, et al. Clinical utility of strict diagnostic criteria for the HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Am J Obstet Gynecol 1996;175:460-464.
137. Sibai BM. The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): much ado about nothing? Am J Obstet Gynecol 1990;162:311-316.
138. Brain MC. Microangiopathic hemolytic anemia. N Engl J Med 1969;281:833-835.
139. Wilke G, Rath W, Schutz E, et al. Haptoglobin as a sensitive marker of hemolysis in HELLP-syndrome. Int J Gynaecol Obstet 1992;39:29-34.
140. Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 2004;103:981-991.
141. George JN. Platelets. Lancet 2000;355:1531-1539.
142. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586-592.
143. Aarnoudse JG, Houthoff HJ, Weits J, et al. A syndrome of liver damage and intravascular coagulation in the last trimester of normotensive pregnancy. A clinical and histopathological study. Br J Obstet Gynaecol 1986;93:145-155.
144. McMahon LP, O'Coigligh S, Redman CW. Hepatic enzymes and the HELLP syndrome: a long-standing error? Br J Obstet Gynaecol 1993;100:693-695.
145. Knapen MF, Mulder TP, Bisseling JG, et al. Plasma glutathione S-transferase alpha 1-1: a more sensitive marker for hepatocellular damage than serum alanine aminotransferase in hypertensive disorders of pregnancy. Am J Obstet Gynecol 1998;178:161-165.
146. Rinehart BK, Terrone DA, Magann EF, et al. Preeclampsia-associated hepatic hemorrhage and rupture: mode of management related to maternal and perinatal outcome. Obstet Gynecol Surv 1999;54:196-202.
147. Wicke C, Pereira PL, Neeser E, et al. Subcapsular liver hematoma in HELLP syndrome: evaluation of diagnostic and therapeutic options-a unicenter study. Am J Obstet Gynecol 2004;190:106-112.
148. Abraham KA, Kennelly M, Dorman AM, et al. Pathogenesis of acute renal failure associated with the HELLP syndrome: a case report and review of the literature. Eur J Obstet Gynecol Reprod Biol 2003;108:99-102.
149. Knopp U, Kehler U, Rickmann H, et al. Cerebral haemodynamic pathologies in HELLP syndrome. Clin Neurol Neurosurg 2003;105:256-261.
150. Sibai BM, Ramadan MK, Usta I, et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 1993;169:1000-1006.
151. Roelofsen AC, van Pampus MG, Aarnoudse JG. The HELLP-syndrome; maternal - fetal outcome and follow up of infants. J Perinat Med 2003;31:201-208.
152. Schlembach D, Munz W, Fischer T. Effect of corticosteroids on HELLP syndrome: a case report. J Perinat Med 2000;28:502-505.
153. Magann EF, Bass D, Chauhan SP, et al. Antepartum corticosteroids: disease stabilization in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). Am J Obstet Gynecol 1994;171:1148-1153.
154. Magann EF, Perry KG Jr, Meydrech EF, et al. Postpartum corticosteroids: accelerated recovery from the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). Am J Obstet Gynecol 1994;171:1154-1158.
155. Vigil-De Gracia P, Garcia-Caceres E. Dexamethasone in the post-partum treatment of HELLP syndrome. Int J Gynaecol Obstet 1997;59:217-221.
156. Yalcin OT, Sener T, Hassa H, et al. Effects of postpartum corticosteroids in patients with HELLP syndrome. Int J Gynaecol Obstet 1998;61:141-148.
157. Isler CM, Barrilleaux PS, Magann EF, et al. A prospective, randomized trial comparing the efficacy of dexamethasone and betamethasone for the treatment of antepartum HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Am J Obstet Gynecol 2001;184:1332-1337; discussion 1337-1339.
158. Isler CM, Magann EF, Rinehart BK, et al. Dexamethasone compared with betamethasone for glucocorticoid treatment of postpartum HELLP syndrome. Int J Gynaecol Obstet 2003;80:291-297.
159. Matchaba P, Moodley J. Corticosteroids for HELLP syndrome in pregnancy. Cochrane Database Syst Rev 2004;1: CD002076.
160. Clenney TL, Viera AJ. Corticosteroids for HELLP (haemolysis, elevated liver enzymes, low platelets) syndrome. BMJ 2004;329:270-272.
161. Shekelle PG, Woolf SH, Eccles M, et al. Clinical guidelines: developing guidelines. BMJ 1999;318:593-596.
162. Martin JN Jr, Perry KG Jr, Blake PG, et al. Better maternal outcomes are achieved with dexamethasone therapy for postpartum HELLP (hemolysis, elevated liver enzymes, and thrombocytopenia) syndrome. Am J Obstet Gynecol 1997;177:1011-1017.
163. Tompkins MJ, Thiagarajah S. HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome: the benefit of corticosteroids. Am J Obstet Gynecol 1999;181:304-309.
164. O'Brien JM, Milligan DA, Barton JR. Impact of high-dose corticosteroid therapy for patients with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Am J Obstet Gynecol 2000;183:921-924.
165. Varol F, Aydin T, Gucer F. HELLP syndrome and postpartum corticosteroids. Int J Gynaecol Obstet 2001;73:157-159.
166. Mecacci F, Carignani L, Cioni R, et al. Time course of recovery and complications of HELLP syndrome with two different treatments: heparin or dexamethasone. Thromb Res 2001;102:99-105.
167. O'Brien JM, Shumate SA, Satchwell SL, et al. Maternal benefit of corticosteroid therapy in patients with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome: impact on the rate of regional anesthesia. Am J Obstet Gynecol 2002;186:475-479.
168. Martin JN Jr, Thigpen BD, Rose CH, et al. Maternal benefit of high-dose intravenous corticosteroid therapy for HELLP syndrome. Am J Obstet Gynecol 2003;189:830-834.
169. Crane JM, Tabarsi B, Hutchens D. The maternal benefits of corticosteroids with HELLP (hemolysis, elevated liver enzymes, low platelet count) syndrome. J Obstet Gynaecol Can 2003;25:650-655.
170. Heller CS, Elliott JP. High-order multiple pregnancies complicated by HELLP syndrome. A report of four cases with corticosteroid therapy to prolong gestation. J Reprod Med 1997;42:743-746.
171. Clark SL, Phelan JR, Allen SH, et al. Antepartum reversal of hematologic abnormalities associated with the HELLP syndrome. A report of three cases. J Reprod Med 1986;31:70-72.
172. Magann EF, Washburne JF, Sullivan CA, et al. Corticosteroid-induced arrest of HELLP syndrome progression in a marginally-viable pregnancy. Eur J Obstet Gynecol Reprod Biol 1995;59:217-219.
173. Dreyfus M, Tissier I, Ndocko MA, et al. Corticosteroid therapy for conservative management in marginally-viable pregnancy complicated by HELLP syndrome. Eur J Obstet Gynecol Reprod Biol 1999;85:233-234.
174. Martin JN, Jr., Rinehart BK, May WL, et al. The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. Am J Obstet Gynecol 1999;180:1373-1384.
175. Visser W, Wallenburg HC. Temporising management of severe pre-eclampsia with and without the HELLP syndrome. Br J Obstet Gynaecol 1995;102:111-117.
176. van Pampus MG, Wolf H, Westenberg SM, et al. Maternal and perinatal outcome after expectant management of the HELLP syndrome compared with pre-eclampsia without HELLP syndrome. Eur J Obstet Gynecol Reprod Biol 1998;76:31-36.
177. Lee G, Foerster J, Paraskevas F, et al. Wintrobe's Clinical Hematology, 10th ed. Baltimore: Williams & Wilkins; 1999.